A PHASE 1a/1b DOSE-ESCALATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION

  • Markman, Ben (Primary Chief Investigator (PCI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date21/04/21 → 31/12/26
View all
View less

Keywords

  • Metastatic solid tumors
  • Anti-cancer therapy
  • Clinical trial